The aetiology of primary focal segmental glomerulosclerosis has proven elusive. Recent data implicates the soluble urokinase-type plasminogen-activator receptor (suPAR) as the circulating permeability factor in the majority of patients with this condition. These exciting findings may dramatically influence the future diagnosis and management of this often resistant glomerular disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
McCarthy, E. T., Sharma, M. & Savin, V. J. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 5, 2115–2121 (2010).
Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952–960 (2011).
Wei, C. et al. Modification of kidney barrier function by the urokinase receptor. Nat. Med. 14, 55–63 (2008).
Wei, C. et al. Circulating suPAR in two cohorts of primary FSGS. J. Am. Soc. Nephrol. 23, 2051–2059 (2012).
Furlan, F. et al. The soluble D2D388–274 fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion. J. Cell Sci. 117, 2909–2916 (2004).
Thuno, M., Macho, B. & Eugen-Olsen, J. suPAR: the molecular crystal ball. Dis. Markers 27, 157–172 (2009).
Backes, Y. et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med. 38, 1418–1428 (2012).
Maas, R. J., Wetzels, J. F. & Deegens, J. K. Serum-soluble urokinase receptor concentration in primary FSGS. Kidney Int. 81, 1043–1044 (2012).
Zhang, B. et al. The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J. Mol. Med. (Berl.) 90, 1407–1420 (2012).
Fornoni, A. et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med. 3, 85ra46 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Jefferson, J., Alpers, C. 'suPAR'-exciting times for FSGS. Nat Rev Nephrol 9, 127–128 (2013). https://doi.org/10.1038/nrneph.2013.15
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.15
